Natera, Inc. NTRA
We take great care to ensure that the data presented and summarized in this overview for Natera, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NTRA
View all-
Vanguard Group Inc Valley Forge, PA12.3MShares$1.9 Billion0.03% of portfolio
-
Black Rock Inc. New York, NY6.77MShares$1.05 Billion0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.74MShares$1.04 Billion0.12% of portfolio
-
Jpmorgan Chase & CO New York, NY6.7MShares$1.04 Billion0.09% of portfolio
-
Farallon Capital Management LLC San Francisco, CA4.43MShares$685 Million3.74% of portfolio
-
Stanley Druckenmiller Duquesne Family Office LLC | New York, Ny3.57MShares$551 Million15.17% of portfolio
-
Fred Alger Management, LLC New York, NY3.02MShares$466 Million2.42% of portfolio
-
State Street Corp Boston, MA2.99MShares$462 Million0.02% of portfolio
-
Rtw Investments, LP New York, NY2.59MShares$401 Million6.7% of portfolio
-
Massachusetts Financial Services CO Boston, MA2.38MShares$368 Million0.13% of portfolio
Latest Institutional Activity in NTRA
Top Purchases
Top Sells
About NTRA
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.
Insider Transactions at NTRA
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Apr 24
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
755
-0.5%
|
$114,760
$152.46 P/Share
|
Apr 23
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
495
-0.64%
|
$74,250
$150.74 P/Share
|
Apr 22
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+1.6%
|
-
|
Apr 22
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
911
-0.6%
|
$131,184
$144.83 P/Share
|
Apr 21
2025
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
86
-0.02%
|
$12,470
$145.85 P/Share
|
Apr 21
2025
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
470
-0.1%
|
$68,150
$145.85 P/Share
|
Apr 21
2025
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
296
-0.1%
|
$43,216
$146.2 P/Share
|
Apr 21
2025
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
SELL
Open market or private sale
|
Direct |
343
-0.11%
|
$49,735
$145.82 P/Share
|
Apr 21
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
1,664
-0.42%
|
$241,280
$145.81 P/Share
|
Apr 21
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
610
-0.4%
|
$88,450
$145.85 P/Share
|
Apr 20
2025
|
Jonathan Sheena |
BUY
Exercise of conversion of derivative security
|
Direct |
190
+0.07%
|
-
|
Apr 20
2025
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
856
+0.38%
|
-
|
Apr 20
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
3,386
+1.66%
|
-
|
Apr 20
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,521
+1.94%
|
-
|
Apr 04
2025
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
3,070
-0.24%
|
$411,380
$134.09 P/Share
|
Apr 03
2025
|
Jonathan Sheena |
SELL
Open market or private sale
|
Indirect |
3,000
-0.81%
|
$417,000
$139.28 P/Share
|
Apr 01
2025
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
3,000
-0.7%
|
$420,000
$140.79 P/Share
|
Apr 01
2025
|
Gail Boxer Marcus |
SELL
Open market or private sale
|
Direct |
4,000
-6.55%
|
$564,000
$141.14 P/Share
|
Apr 01
2025
|
Gail Boxer Marcus |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+13.38%
|
$64,000
$16.14 P/Share
|
Apr 01
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
15,898
-1.92%
|
$2,225,720
$140.74 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 468K shares |
---|---|
Exercise of conversion of derivative security | 909K shares |
Open market or private sale | 1.08M shares |
---|---|
Bona fide gift | 12.6K shares |